CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent

Journal of Gastrointestinal Surgery

Volumn 13, Issue 2, 2009, Pages 349-353

  Hernandez, Jonathan M ^a   Cowgill, Sarah M ^a   Al Saadi, Sam ^a   Collins, Amy ^a   Ross, Sharona B ^a   Cooper, Jennifer ^a   Villadolid, Desireé ^a   Zervos, Emmanuel ^a   Rosemurgy, Alexander ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

CA 19 9 velocity; Pancreatic cancer; Survival

Indexed keywords

CA 19-9 ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; PANCREAS RESECTION; PANCREAS TUMOR; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 59149084072     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0696-3     Document Type: Article

References (15)

1. M Bloomston TS Bekaii-Saab K Kosuri 2006 Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection Pancreas 33 246 249 doi:10.1097/01.mpa. 0000236726.34296.df
2. CJ Wray SA Ahmad JB Matthews AM Lowy 2005 Surgery for pancreatic cancer: recent controversies and current practice Gastroenterology 6 1626 1641 doi:10.1053/j.gastro.2005.03.035
3. VJ Picozzi RA Kozarek LW Traverso 2003 Interferon-based adjuvant chemoradiation after pancreaticodudenectomy for pancreatic cancer Am J Surg 185 476 80 doi:10.1016/S0002-9610(03)00051-5
4. GY Locker S Hamilton J Harris 2006 ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 33 5313 5327 doi:10.1200/JCO.2006.08.2644
5. H Koprowski Z Steplewski K Mitchell M Herlyn D Herlyn P Fuhrer 1979 Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genet 5 957 971 doi:10.1007/BF01542654
6. J Magnani B Nilsson M Brockhaus 1982 A Monoclonal antibody defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N- fucopenteose II J Biol Chem 257 14365 14369
7. O Nazli AD Bozdag T Tansug 2000 The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma Hepatogastroenterology 47 1750 1752
8. B Slesak A Harlozinska-Szmyrka W Knast 2000 Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9 Cancer 89 83 88
9. C Ferrone D Finkelstein S Thayer A Muzikansky 2006 Perioperative CA-19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol 24 2897 2902 doi:10.1200/JCO.2005.05.3934
10. RC Montgomery JP Hoffman LB Riley 1997 Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas Ann Surg Oncol 7 551 556 doi:10.1007/BF02305535
11. F Safi W Schlosser S Falkenreck 1998 Prognostic value of CA 19-9 serum course in pancreatic cancer Hepatogastroenterology 19 253 259
12. AH Ko J Hwang AP Venook 2005 Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer Br J Cancer 2 195 199 doi:10.1038/sj.bjc.6602687
13. NR Maisey AR Norman A Hill 2005 CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials Br J Cancer 93 740 743 doi:10.1038/sj.bjc.6602760
14. A Rosemurgy J Harris J Langleben E Casper S Goode A Rasmussen 1999 Marimastat in patients with advanced pancreatic cancer. A dose-finding study Am J Clin Oncol 3 247 252 doi:10.1097/00000421-199906000-00007
15. C Ziske C Schlie M Gorschluter 2003 Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine Br J Cancer 89 1413 1417 doi:10.1038/sj.bjc.6601263